



CONSOLIDATED FINANCIAL STATEMENTS

TERRABIOGEN TECHNOLOGIES INC.

(Expressed in Canadian Dollars)

For the three months ended September 30, 2013

(Unaudited – Prepared by Management)

Notice: These consolidated interim financial statements have been prepared by management and they have not been reviewed by the Company's external auditors

NOTICE OF NO AUDITOR REVIEW OF CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The accompanying unaudited consolidated interim financial statements of TerraBioGen Technologies Inc. for the three months ended September 30, 2013 have been prepared by management of the Company and approved by the Company's Audit Committee and the Company's Board of Directors.

Under National Instrument 51-102, Part 4, subsection 4.3 (3)(a), if an auditor has not performed a review of the consolidated interim financial statements, they must be accompanied by a notice indication that an auditor has not reviewed the financial statements.

The accompanying unaudited consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these interim financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(Expressed in Canadian Dollars)
(Unaudited – Prepared by management)

	September 30, 2013	June 30, 2013
ASSETS		
Current		
Cash	\$ -	\$ 115,737
Amounts receivable (Note 6)	3,913	12,841
Deposits and prepaid expenses (Note 7)	7,072	12,416
CURRENT ASSETS	10,985	140,994
Property and equipment (Note 8)	439,833	470,128
Long term assets	36,106	23,144
TOTAL ASSETS	\$ 486,924	\$ 634,266
LIABILITIES		
Current		
Bank loan	\$ 25,597	\$ -
Accounts payable and accrued expenses	224,882	327,700
Customer deposits	100,000	100,000
Term loan (Note 10)	81,231	81,231
CURRENT LIABILITIES	431,710	508,931
Provision for dismantling (Note 11)	5,867	5,816
TOTAL LIABILITIES	437,577	514,747
SHAREHOLDERS' EQUITY		
Share capital (Note 13)	36,756,110	36,326,110
Commitment to issue shares (Note 13)	-	210,000
Contributed surplus (Note 13)	1,861,374	1,861,374
Deficit	(38,568,137)	(38,277,965)
SHAREHOLDERS' EQUITY (DEFICIENCY)	49,347	119,519
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 486,924	\$ 634,266

Operations (Note 1)
Commitments (Note 15)
Subsequent Events (Note 19)

These consolidated interim financial statements were approved for issue by the Board of Directors on November 26, 2013 and are signed on its behalf by:

"Blair Heffelfinger"
Director

"Theodore Deuel"
Director

The accompanying notes are an integral part of these consolidated interim financial statements.

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

For the Three Months ended September 30

(Expressed in Canadian Dollars)

(Unaudited – prepared by management)

	2013	2012
REVENUE		
Other income	\$ 257	\$ 619
TOTAL REVENUE	257	619
EXPENSES		
Plant and operations	-	197,750
Administration	126,266	90,526
Depreciation	33,042	159,467
Research and development	128,864	75,955
Interest	2,206	1,695
Interest on long term debt	-	812
Accretion on provision for dismantling (Note 12)	51	2,249
TOTAL EXPENSES	290,429	528,454
NET LOSS AND COMPREHENSIVE LOSS	(290,172)	(527,835)
Deficit, beginning of period	(38,277,965)	(36,437,130)
DEFICIT, end of period	\$ (38,568,137)	\$ (36,964,965)
BASIC AND DILUTED LOSS PER SHARE	\$ (0.19)	\$ (0.38)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	1,520,203	1,374,442

The accompanying notes are an integral part of these consolidated interim financial statements.

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED INTERIM STATEMENTS OF SHAREHOLDERS' EQUITY
For the Periods Ended June 30, 2013 and September 30, 2013
(Expressed in Canadian Dollars)

	<u>Common shares</u>						
	<u>Number of Shares</u>	<u>Amount</u>	<u>Commitment to Issue Shares</u>	<u>Contributed Surplus</u>	<u>Deficit</u>	<u>Total Equity</u>	
Balance at July 1, 2012	1,374,495	\$ 34,967,762	\$ -	\$ 1,844,734	\$ (36,437,130)	\$ 375,366	
Shares repurchased	(107)	(1,177)	-	-	-	(1,177)	
Share-based compensation	-	-	-	7,924	-	7,924	
Comprehensive loss for the period	-	-	-	-	(527,835)	(527,835)	
Balance at Sept. 30, 2012	<u>1,374,388</u>	<u>\$ 34,966,585</u>	<u>\$ -</u>	<u>\$ 1,852,658</u>	<u>\$ (36,964,965)</u>	<u>\$ (145,722)</u>	
Balance at July 1, 2013	1,510,388	\$ 36,326,110	\$ 210,000	\$ 1,861,374	\$ (38,277,965)	\$ 119,519	
Shares issued for cash	43,000	430,000	(210,000)	-	-	220,000	
Comprehensive loss for the period	-	-	-	-	(290,172)	(290,172)	
Balance at Sept. 30, 2013	<u>1,553,388</u>	<u>\$ 36,756,110</u>	<u>\$ -</u>	<u>\$ 1,861,374</u>	<u>\$ (38,568,137)</u>	<u>\$ 49,347</u>	

The accompanying notes are an integral part of these consolidated interim financial statements.

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

For the Three Months ended September 30

(Expressed in Canadian Dollars)

(Unaudited – prepared by management)

	2013	2012
OPERATIONS		
Net Income (Loss)	\$ (290,172)	\$ (527,835)
Items not involving cash:		
Depreciation	33,042	159,467
Accretion on provision for dismantling	51	2,249
Share-based compensation	-	7,924
	(257,079)	(358,195)
Changes in non-cash working capital balances:		
Decrease (increase) in prepaid expenses and deposits	5,344	(3,948)
Increase (decrease) in accounts payable and accrued expenses	(102,818)	(10,270)
Decrease (increase) in accounts receivable	8,928	45,724
CASH USED IN OPERATING ACTIVITIES	(345,625)	(326,689)
INVESTING		
Increase in long term assets	(12,962)	-
Increase in property and equipment	(2,747)	(28,521)
CASH USED IN INVEST ACTIVITIES	(15,709)	(28,521)
FINANCING		
Increase in bank loans	25,597	-
Shares issued	430,000	-
Decrease in share subscriptions	(210,000)	-
Reduction against plant dismantling	-	(83,160)
CASH PROVIDED BY FINANCING ACTIVITIES	245,597	(88,504)
Increase (decrease) in cash and cash equivalents	(115,737)	(443,714)
Cash and cash equivalents, beginning of period	115,737	573,721
CASH AND CASH EQUIVALENTS, end of period	\$ -	\$ 130,007

The accompanying notes are an integral part of these consolidated interim financial statements.

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED INTERIM STATEMENTS OF EXPENSES

For the Three Months ended September 30

(Expressed in Canadian Dollars)

(Unaudited – prepared by management)

	2013	2012
ADMINISTRATION:		
Wages and consulting fees	\$ 70,306	\$ 40,599
Stock option expense	-	7,924
Accounting and professional fees	15,000	15,000
Office expenses	25,518	16,040
Rent and utilities	6,834	-
Legal fees	4,043	8,575
Travel & entertainment	1,185	640
Transfer agent and regulatory fees	1,180	1,748
Directors fees and expenses	2,200	-
	\$ 126,266	\$ 90,526
RESEARCH AND DEVELOPMENT:		
Wages and benefits	\$ 53,290	\$ 59,745
Rent and utilities	22,536	-
Contractors and growing trials	35,884	7,223
Patents	-	5,716
Other expenses	17,154	8,848
Government assistance (note 12)	-	(5,577)
	\$ 128,864	\$ 75,955
PLANT AND OPERATIONS:		
Wages and benefits	\$ -	\$ 89,275
Rent & Property Tax	-	30,821
Repairs and maintenance	-	20,553
Power, water and sewer	-	15,342
Supplies & materials	-	38,308
Other	-	3,451
	\$ -	\$ 197,750

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

1. OPERATIONS

TerraBioGen Technologies Inc. was incorporated in British Columbia, Canada, on August 17, 1993; on January 21, 2011, the Company changed its name from International Bio Recovery Corp. The Company's shares were traded on the TSX Venture Exchange until June 12, 2012 when they were delisted at the Company's request.

The Company has identified active ingredients that impart growth promotion and disease suppression in plants, and is planning to commercialize this technology. The Company closed its pilot plant in North Vancouver, British Columbia in 2013 and moved to a new facility in Burnaby, British Columbia which is used for research and development, and to provide product for growing trials.

These consolidated financial statements have been prepared on a going concern basis. At September 30, 2013, the Company had a working capital deficit of \$420,725, an accumulated deficit of \$38,568,137, and incurred a net loss of \$290,172 for the three months then ended (2012 - \$527,835). The Company's ability to continue its operations and to realize assets at their carrying values is dependent upon generating revenues sufficient to cover its operating costs, the continued support of its shareholders, obtaining additional financing, and ultimately, generating profitable operations and positive operating cash flows. Failure to obtain sufficient financing or other appropriate arrangements would require the Company's assets and liabilities to be restated on a liquidation basis which would differ significantly from the going concern basis. These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern.

The address of the Company's corporate office and principal place of business is 8536 Baxter Place, Burnaby, BC V5A 4T8.

2. BASIS OF PRESENTATION

Statement of Compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and the interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

Approval of the Financial Statements

The consolidated financial statements of the Company for the three months ended September 30, 2013 were reviewed by the Audit Committee and approved and authorized for issuance by the Board of Directors on November 26, 2013.

Basis of Presentation

These consolidated financial statements have been prepared on the historical cost basis except for financial assets and financial liabilities that have been measured at fair value as described in Note 3. The accounting policies applied in these consolidated financial statements as described below, have been applied consistently to all periods presented as if the policies have always been in effect.

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Genica Inc., which has been inactive since June 2012. All intercompany balances and transactions have been eliminated upon consolidation.

The comparative figures presented in these consolidated financial statements are in accordance with IFRS.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION (continued)

Use of estimates

The preparation of these consolidated financial statements, in compliance with IFRS, requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. Significant areas requiring the use of management estimates include the fair value of property and equipment, deferred income tax asset valuations, provision for dismantling, and fair value measurements for financial instruments and share-based compensation. Actual results could differ from those estimates.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue recognition – The Company earns revenue from interest on funds in its bank accounts. Revenue is recognized when the significant risks and rewards are transferred to the customers, persuasive evidence of the arrangement exists, the price is fixed and determinable and collection of the relevant receivable is probable, which is generally at the completion of the transaction.

Cash and cash equivalents – The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Property and equipment – Property and equipment are recorded at historical cost less accumulated depreciation and any accumulated impairment losses. The depreciation is determined based on the following annual rates:

Leasehold improvements	straight-line
Laboratory equipment	20 - 30% declining balance
Other equipment	20 - 30% declining balance
Vehicles	30% declining balance

One-half of the above rates are applied in the year of acquisition.

The assets' useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals, if any, are determined by comparing the proceeds with the carrying amount and are recognized in the consolidated statements of loss and comprehensive loss.

Research and development – Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets criteria for deferral and depreciation.

Government assistance – Government grants are recognized and recorded as a reduction of research and development expenses where there is reasonable assurance that the grant will be received and all attaching conditions are complied with. Reimbursements of eligible costs pursuant to government corporate programs are recorded as a reduction of total costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. Claims not settled by the consolidated statement of financial position date are recorded as a receivable on the consolidated statement of financial position. The determination of the amount of the claim, and hence the receivable amount, requires management to make calculations based on its interpretation of eligible expenditures in accordance with the terms of the programs. The reimbursement claims submitted by the Company are subject to review by the relevant government and corporate agencies. Although the Company has used its best judgment and understanding of the related program agreements in determining the receivable amount, it is possible that the amounts could increase or decrease by a material amount in the near term dependent on the review and audit by the government agency. Any funds received in advance of expenditures or eligibility requirements are recorded as deferred contributions on the consolidated statement of financial position and adjusted as subsequent claims are made by the Company.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Government assistance (continued)

If a grant becomes repayable, it will be treated as a change in estimate. Where the original grant related to income, the repayment should be applied first against any related undepreciated deferred contributions, and any excess will be recognized as an expense.

Leases – Leases are classified as either capital or operating leases. Leases that transfer substantially all of the benefits and risks incidental to the ownership of equipment are classified as capital leases. At the inception of a capital lease, the equipment and an obligation is recorded at its fair value. Equipment under a capital lease is depreciated on a declining-balance basis at rates varying from 20 to 30% per annum, which approximates the equipment's estimated useful life. All other leases are classified as operating leases.

Decommissioning provisions – The Company's activities give rise to dismantling, decommissioning and site disturbance re-mediation activities. Provision is made for the estimated cost of site restoration and capitalized in the relevant asset category.

Decommissioning provisions are measured at the present value of management's best estimate of expenditure required to settle the present obligation at the consolidated statement of financial position date. Subsequent to initial measurement, the obligation is adjusted at the end of each period to reflect the passage of time and changes in the estimated future cash flows underlying the obligation. The increase in the provision due to the passage of time is recognized as finance costs whereas increases/decreases due to changes in the estimated future cash flows are recorded against the related asset. Actual costs incurred upon settlement of the decommissioning provisions are charged against the provision to the extent the provision was established. As at June 30, 2013 and September 30, 2013, the Company has recognized a provision for dismantling of \$5,816 as described in Note 11.

Impairment – The carrying amounts of the Company's property and equipment are reviewed at each reporting date for indicators of impairment. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the amount of the impairment, if any. The recoverable amount of an asset is evaluated at the cash generating unit level ("CGU"), which is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or group of assets. The recoverable amount of a CGU is the greater of its fair value less costs to sell and its value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in arm's length transaction between knowledgeable and willing parties, less the costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of CGU's are allocated to reduce the carrying amounts of the other assets in the unit (group of units) on a pro rata basis.

Impairment losses recognized in prior years are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depletion and depreciation, if no impairment loss had been recognized.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Deferred income taxes – The Company utilizes the asset and liability method of accounting for income taxes. Under the liability method, deferred income taxes and liabilities are recognized to reflect the expected deferred tax consequences arising from temporary differences between the carrying value and the tax bases of the deferred tax assets and liabilities, and are measured using the enacted or substantively enacted tax rates expected to apply when the asset is realized or the liability settled. Deferred income tax assets are recognized to the extent that it is probable the asset will be realized.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

Share-based compensation – The Company operates an incentive stock option plan. Share-based payments to employees are measured at the fair value of the instruments issued and amortized over the vesting periods. Share-based payments to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued, if it is determined the fair value of the goods or services cannot be reliably measured, and are recorded at the date the goods or services are received. The fair value of share-based compensation is charged to the consolidated statement of operations and comprehensive income (loss) with a corresponding credit recorded to contributed surplus. The fair value of options is determined using a Black-Scholes option pricing model. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest.

Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to the consolidated statement of operations and comprehensive loss/income over the remaining vesting period.

The Black-Scholes option pricing model requires management to make estimates, which are subjective and may not be representative of actual results. Changes in assumptions can materially affect estimates of fair values.

Share capital – Common shares issued by the Company are classified as equity. Costs directly attributable to the issue of common shares, share purchase warrants and share options are recognized as a deduction from equity. Equity instruments issued to agents as financing costs are measured at their fair value at the date of grant.

Foreign currency translation – The functional currency of the Company, being the currency of the primary economic environment in which the Company operates, is the Canadian dollar. Foreign denominated monetary assets and liabilities are translated at the year-end rates of exchange. Non-monetary items are translated using the exchange rates prevailing at the date of the transaction. Revenues and expenses are translated using average rates of exchange during the year. Exchange gains or losses arising from currency translation are recognized in the consolidated statement of operations and comprehensive loss.

Earnings per share – Basic earnings/loss per share is computed by dividing the net income or loss applicable to common shares of the Company by the weighted average number of common shares outstanding for the relevant period.

Diluted earnings/loss per common share is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted. This follows the treasury stock method in which the dilutive effect on loss per share is recognized based on the proceeds that could be obtained from the exercise of options, warrants, and similar instruments. It assumes the proceeds would be used to purchase common shares at the average market price during the year.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Financial instruments – All financial assets are initially recorded at fair value and designated upon inception into one of the following four categories: held to maturity, available-for-sale, loans and receivables or at fair value through profit or loss ("FVTPL").

Financial assets classified at fair value through profit or loss are measured at fair value with unrealized gains and losses recognized through comprehensive loss. Cash is classified at fair value through profit or loss.

Financial assets classified as loans and receivables and held to maturity are measured at amortized cost. Amounts receivable are classified as loans and receivables.

Financial assets classified as available-for-sale are measured at fair value with unrealized gains and losses recognized in other comprehensive income except for losses in value that are considered other than temporary. At June 30, 2013, the Company has not classified any financial assets as available-for-sale.

Transaction costs associated with financial assets classified at fair value through profit or loss are expensed as incurred, while transaction costs associated with all other financial assets are included in the initial carrying amount of the asset. All financial liabilities are initially recorded at fair value and designated upon inception at fair value through profit or loss or other financial liabilities.

Financial liabilities classified as other financial liabilities are measured at amortized cost. Accounts payables, customer deposits and term loan are classified as other financial liabilities.

Financial liabilities classified at fair value through profit or loss are measured at fair value with unrealized gains and losses recognized through comprehensive loss. At September 30, 2013, the Company has not classified any financial liabilities at fair value through profit or loss.

4. NEW ACCOUNTING PRONOUNCEMENTS

A number of new standards, and amendments to standards and interpretations, are not yet effective for the three months ended September 30, 2013, and have not been applied in preparing these consolidated financial statements.

- a) Effective for annual periods beginning on or after July 1, 2013:

New Standard IFRS 10, "Consolidated Financial Statements"

In May 2011, the IASB issued IFRS 10 to replace portions of IAS 27, "Consolidated and Separate Financial Statements" and interpretation SIC-12, "Consolidated - Special Purpose Entities". IFRS 10 incorporates a single model for consolidating all entities that are controlled and revises the definition of control to be "An investor controls an investee when it is exposed, or has rights, to variable returns from its involvement with the investee and has the current ability to affect those returns through its power over the investee". Along with control, the new standard also focuses on the concept of power, both of which will include a use of judgment and a continuous reassessment as facts and circumstances change.

New standard IFRS 11, "Joint Arrangements"

In May 2011, the IASB issued IFRS 11 to replace IAS 31, "Interest in Joint Ventures". The new standard will apply to the accounting for interest in joint arrangements where there is joint control. Joint arrangements will be separated into joint ventures and joint operations. The structure of the joint arrangement will no longer be the most significant factor on classifying a joint arrangement as either a joint operation or a joint venture. Proportionate consolidations will be removed and replaced with equity accounting.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

4. NEW ACCOUNTING PRONOUNCEMENTS (continued)

New standard IFRS 12, "Disclosure of Interest in Other Entities"

In May 2011, the IASB issued IFRS 12. The new standard includes disclosure requirements about subsidiaries, joint ventures and associates, as well as unconsolidated structured entities and replaces existing disclosure requirements.

New standard IFRS 13, "Fair Value Measurement"

In May 2011, the IASB issued IFRS 13. The new standard converges IFRS and US GAAP on how to measure fair value and the related fair value disclosures. The new standard creates a single source of guidance for fair value measurements, where fair value is required or permitted under IFRS, by not changing how fair value is used but how it is measured. The focus will be on an exit price.

b) Effective for annual period beginning on or after July 1, 2015:

New standard IFRS 9, "Financial Instruments"

Partial replacement of IAS 39, "Financial Instruments: Recognition and Measurement". IFRS 9 introduces new requirements for how an entity should classify and measure financial assets that are in the scope of IAS 39. The standard requires all financial assets to be classified on the basis of the entity's business model for managing the financial assets, and the contractual cash flow characteristics of the financial asset. A financial asset is measured at amortized cost if two criteria are met: (a) the objective of the business model is to hold the financial asset for the collection of the contractual cash flows, and (b) the contractual cash flows under the instrument solely represent payments of principal and interest. If a financial asset meets the criteria to be measured at amortized cost, it can be designated at fair value through profit or loss under the fair value option, if doing so would significantly reduce or eliminate an accounting mismatch. If a financial asset does not meet the business model and contractual terms criteria to be measured at amortized cost, then it is subsequently measured at fair value. In October 2010, the IASB issued additions to IFRS 9 relating to accounting for financial liabilities. Under the new requirements, an entity choosing to measure a financial liability at fair value will present the portion of any change in its fair value due to changes in the entity's own credit risk in other comprehensive income, rather than within profit or loss.

The Company has not early adopted these revised standards and is currently assessing the impact they will have on the consolidated financial statements.

5. FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash, amounts receivable, accounts payable, customer deposits, loans payable, and term loan.

The following table summarizes information regarding the carrying and fair values of the Company's financial instruments:

	September 30, 2013		June 30, 2013	
	Fair Value	Carrying Value	Fair Value	Carrying Value
FVTPL asset (i)	\$ -	\$ -	\$ 115,737	\$ 115,737
Other financial liabilities (ii)	\$ 345,613	\$ 345,613	\$ 399,337	\$ 399,377

i) Cash

ii) Accounts payable, customer deposits, loans payable, and term loan

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

5. FINANCIAL INSTRUMENTS (continued)

Fair value

The Company classifies its fair value measurements in accordance with an established hierarchy that prioritizes the inputs in valuation techniques used to measure fair value as follows:

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the assets or liabilities, either directly (i.e. as prices) or indirectly (i.e. from derived prices); and

Level 3 – inputs for the asset or liability that are not based upon observable market data

The following table sets forth the Company's financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:

	Level 1	Level 2	Level 3	Total
Cash	\$ -	\$ -	\$ -	-

The Company believes the recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates.

Foreign exchange risk

Most of the Company's operating expenditures are denominated in Canadian dollars and certain operating expenses are in United States dollars. The Company's exposure to foreign currency risk arises primarily on fluctuations between the Canadian dollar and the United States dollar.

The Company has not entered into any derivative instruments to manage foreign exchange fluctuations.

At September 30, 2013 and June 30, 2013, the Company had no significant foreign currency denominated assets or financial liabilities.

Interest rate risk

The Company is subject to interest on its bank loans and shareholder loans which are at negotiated rates of interest. Significant increase in these interest rates would result in increased costs for the Company.

Credit risk

Credit risk is the risk of an unexpected loss if a counterparty to a financial instrument fails to meet its contractual obligations. The credit risk associated with cash is believed to be minimal as cash is on deposit with Canadian banks that are believed to be creditworthy. Amounts receivable is comprised primarily of amounts due from the Government of Canada. The Company does not believe it is exposed to significant credit risk.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure and financial leverage as outlined above.

The Company monitors its ability to meet its short-term operating expenditures by raising additional funds through share issuance when required. All of the Company's financial liabilities have contractual maturities of 30 days or are subject to normal trade terms.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

6. AMOUNTS RECEIVABLE

	September 30, 2013		June 30, 2013	
Goods and Services Tax	\$	3,806	\$	11,040
Other		<u>107</u>		<u>1,801</u>
	\$	<u>3,913</u>	\$	<u>12,841</u>

7. DEPOSITS AND PREPAID EXPENSES

	September 30, 2013		June 30, 2013	
Prepaid insurance premiums	\$	6,482	\$	4,513
Deposits		-		7,313
Other		<u>590</u>		<u>590</u>
	\$	<u>7,072</u>	\$	<u>12,416</u>

8. PROPERTY AND EQUIPMENT

Three months ended September 30, 2013

	Laboratory equipment	Vehicles	Leasehold improvements	Other	Total
Costs					
Balance, July 1, 2013	\$ 614,340	\$ 12,115	\$ 93,426	\$ 189,907	\$ 909,788
Additions and transfers	-	-	2,184	563	2,747
Balance, Sept. 30, 2013	\$ 614,340	\$ 12,115	\$ 95,610	\$ 190,470	\$ 912,535
Accumulated depreciation					
Balance July 1, 2013	\$ 266,487	\$ 1,817	\$ 1,825	\$ 169,531	\$ 439,660
Depreciation	24,875	773	6,067	1,327	33,042
Balance, Sept. 30, 2013	\$ 291,362	\$ 2,590	\$ 7,892	\$ 170,858	\$ 472,702
Carrying amount at Sept. 30, 2013	\$ 322,978	\$ 9,525	\$ 87,718	\$ 19,612	\$ 439,833

Year ended June 30, 2013

	Plant and equipment	Vehicles	Laboratory equipment	Office building	Leasehold improvements	Other	Total
Costs							
Balance, July 1, 2012	\$ 4,901,173	\$ 356,192	\$ 357,664	\$ 140,706	\$ -	\$ 195,672	\$ 5,951,407
Additions and transfers	-	12,115	256,676	-	93,426	6,952	369,169
Change in estimate	(52,144)	-	-	-	-	-	(52,144)
Disposition	(4,849,029)	(356,192)	-	(140,706)	-	(12,717)	(5,347,888)
Balance, June 30, 2013	\$ -	\$ 12,115	\$ 614,340	\$ -	\$ 93,426	\$ 189,907	\$ 909,788
Accumulated depreciation							
Balance July 1, 2012	\$ 4,573,012	\$ 342,313	\$ 181,084	\$ 125,123	\$ -	\$ 176,218	\$ 5,397,750
Depreciation	276,017	4,940	85,403	15,583	1,825	6,030	389,798
Disposition	(4,849,029)	(345,436)	-	(140,706)	-	(12,717)	(5,347,888)
Balance, June 30, 2013	\$ -	\$ 1,817	\$ 266,487	\$ -	\$ 1,825	\$ 169,531	\$ 439,660
Carrying amount at June 30, 2013	\$ -	\$ 10,298	\$ 347,853	\$ -	\$ 91,601	\$ 20,376	\$ 470,128

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

9. BANK LOAN

The Company has a loan agreement with HSBC Bank Canada under a credit facility. The credit facility consists of a \$100,000 operating loan which bears interest at the bank's prime rate plus 1.25% per annum and is payable on demand. The loan is secured by a general security agreement providing a first security interest in all of the Company's assets and ranks ahead of all other loans. As at September 30, 2013, the Company had drawn \$25,597 against this credit facility and, as at June 30, 2013, the Company had no outstanding drawings against this credit facility.

10. TERM LOAN

In December 2010, the Company converted \$81,231 of accrued interest on loans payable into a term loan. This term loan bears interest at 4% per annum and is repayable by October 31, 2013. The loan ranks behind the general security agreement on the bank loan described in Note 9, and is secured by an interest in all present and future personal property of the Company and a floating charge on all of the Company's other present and future property.

See Note 20.

11. PROVISION FOR DISMANTLING

The Company is required to dismantle certain parts of its leasehold improvements when it vacates its premises in Burnaby at the end of the lease term.

In order to vacate its previous premises in North Vancouver in June 2013, the Company needed to dismantle and move certain parts of its plant and equipment.

The following table presents the reconciliation of the opening and closing aggregate carrying amount of the provision for dismantling associated with property and equipment, and leasehold improvements:

	Three months ended September 30, 2013	Year ended June 2013
Opening balance	\$ 5,816	\$ 350,649
Addition	-	5,816
Reduction in dismantling provision	-	(119,798)
Actual costs incurred against provision	-	(234,017)
Accretion expense	51	3,166
Ending balance	\$ 5,867	\$ 5,816

During the year ended June 30, 2013, the Company reduced the decommissioning provision as a result of a revision in the estimated obligation. This reduction resulted in a reduction of \$52,144 in the capitalized dismantling provision (see Note 8) and \$44,017 was recorded as a loss on change in dismantling provision.

The amounts in the three months to September 30, 2013 relate to dismantling of the leasehold improvements at the current premises at the end of the lease term.

13. SHARE CAPITAL

Authorized Share Capital

At September 30, 2013, the Company has authorized share capital of 2,500,000 common shares without par value and 2,500,000 of preferred shares without par value. None of the preferred shares have been issued.

Issued and outstanding: See Consolidated Statement of Changes in Equity.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

13. SHARE CAPITAL (continued)

The following share transactions occurred:

- a) On March 7, 2013, the Company issued 90,000 units at a price of \$10.00 per unit for gross proceeds of \$900,000. Each unit consisted of one common share and one warrant exercisable at \$12.00 per share until March 7, 2018.
- b) On May 31, 2013, the Company issued 41,000 units at a price of \$10.00 per unit for gross proceeds of \$410,000. Each unit consisted of one common share and one warrant exercisable at \$12.00 per share until May 31, 2018.
- c) On September 9, 2013, the Company issued 43,000 units at a price of \$10.00 per unit for gross proceeds of \$430,000. Each unit consisted of one common share and one warrant exercisable at \$12.00 per share until September 5, 2018. As at June 30, 2013, the Company had received \$210,000 towards this financing.

Shares for Debt

On May 31, 2013, the Company issued 5,000 common shares at a price of \$10.00 per share and 5,000 share purchase warrants exercisable at a price of \$12.00 until May 31, 2018 to convert \$50,000 of amounts payable.

No value was allocated to the warrants included in the above-noted unit offerings given that the warrants had no intrinsic value at the time of issuance of the unit offerings.

Warrants – Details of share purchase warrants during the periods ended September 30, 2013 and June 30, 2013 are as follows:

	Three Months Ended Sept. 30, 2013		Year Ended June 30, 2013	
	Number	Weighted Average Exercise Price	Number	Weighted Average Exercise Price
Outstanding, beginning of year	246,249	\$ 13.34	391,854	\$ 13.52
Issued	43,000	12.00	136,000	12.00
Expired	-	-	(281,605)	12.95
Outstanding, end of year	289,249	\$ 13.14	246,249	\$ 13.34

During the year ended June 30, 2013, an aggregate of 136,000 warrants were issued at an exercise price of \$12.00 and 281,605 warrants had expired. No warrants were exercised or forfeited. During the three months ended September 30, 2013, 43,000 warrants were issued at an exercise price of \$12.00 and no warrants expired. No warrants were exercised or forfeited. As at September 30, 2013 and June 30, 2013, the intrinsic value of the warrants were \$Nil.

As at September 30, 2013, the Company had share purchase warrants outstanding and exercisable as follows:

Number of Warrants Outstanding and Exercisable		Exercise Price per Share	Expiry Date
Sept. 30, 2013	June 30, 2013		
110,249	110,249	\$15.00	December 10, 2013
90,000	90,000	\$12.00	March 7, 2018
46,000	46,000	\$12.00	May 31, 2018
43,000	-	\$12.00	Sept. 5, 2018
289,249	246,249		

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

13. SHARE CAPITAL (continued)

Stock options

The Company grants stock options to directors, officers, employees and consultants as compensation for services, pursuant to its Incentive Stock Option Plan (the "Plan") instituted in 1999 and amended, most recently in July 2010. Options issued pursuant to the Plan have an exercise price as determined by the Board. Options have a maximum expiry period of ten years from the grant date. The number of options, which may be issued under the plan, is limited to no more than 10% of the Company's issued and outstanding shares on the grant date. The aggregate number of options granted to any one optionee in a twelve-month period is limited to 5% of the Company's issued shares at the time the options are granted. Options granted under the plan are subject to vesting terms determined by the Board of Directors of the Company.

A summary of the Company's share options at September 30, 2013 and June 30, 2013 and the changes for the periods ended on those dates is presented below:

	September 30, 2013		June 30, 2013	
	Options Outstanding	Weighted Average Exercise Price	Options Outstanding	Weighted Average Exercise Price
Opening balance	68,000	\$15.40	73,000	\$15.61
Granted	-	-	-	-
Forfeited or expired	(6,500)	(15.00)	(5,000)	(18.50)
Ending balance	61,500	\$15.44	68,000	\$15.40

As at September 30, 2013, the Company had the following share options outstanding and exercisable:

September 30, 2013			
Quantity Outstanding	Quantity Exercisable	Exercise Price	Expiry Date
2,000	2,000	\$15.00	Mar 3, 2014
2,500	2,500	\$50.00 (a)	May 31, 2014
2,000	-	\$75.00 (b)	May 31, 2015
20,000	20,000	\$12.00	July 5, 2015
14,000	14,000	\$10.00	July 5, 2015
16,000	16,000	\$12.00	Dec 15, 2015
5,000	5,000	\$12.00	Oct 3, 2016
61,500	59,000		

On December 7, 2011, the Company amended options, as follows:

a) the exercise price on 2,000 options vesting on June 1, 2013 and expiring May 31, 2014 was changed from \$125.00 to \$50.00 and the quantity was increased to 2,500 options; and

b) the exercise price on 2,500 options vesting on June 1, 2014 and expiring May 31, 2015 was changed from \$175.00 to \$75.00 and the quantity was decreased to 2,000 options.

The weighted average contractual life remaining on the above options is 1.87 years (June 30, 2013 – 1.93 years)

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

13. SHARE CAPITAL -continued

The Company did not grant any options to directors and officers during the year ended June 30, 2013 nor the three months ended September 30, 2013. Total share-based compensation for the three months ended September 30, 2013 was \$Nil (year ended June 30, 2013 - \$16,640) which has been expensed to the consolidated statement of loss and comprehensive loss.

14. RELATED PARTY TRANSACTIONS AND KEY MANAGEMENT PERSONNEL

For the three months ended September 30, 2013 and September 30, 2012, the Company has identified its directors and senior officers as its key management personnel and the compensation costs for key management personnel and companies related to them were recorded at their exchange amounts as agreed upon by transacting parties.

The compensation costs for key management personnel for the three months ended September 30, 2013 and September 30, 2012 are as follows:

	2013	2012
Salaries and benefits	\$ 117,544	\$ 106,139
Share-based compensation	-	6,380
	<u>\$ 112,519</u>	<u>\$ 112,519</u>

Other related party transactions during the three months ended September 30, 2013:

- a) Consulting fees of \$15,000 (2012 - \$15,000) were expensed for services provided by a company controlled by an officer, and consulting fees of \$3,900 (2012 - \$4,650) were expensed for services provided by a director.
- b) Accounts payable and accrued expenses include fees payable to directors of \$3,800 (2012 - \$Nil). Fees to directors of \$2,200 (2012 - \$Nil) were expensed during the three months, and fees of \$Nil (2012 - \$11,400) were paid to directors during the three months ended September 30, 2013.
- c) During the year ended June 30, 2012, the Company obtained a loan from a director of \$50,000. In February 2012, the director subscribed for a private placement of 25,000 common shares at \$10.00 per share and the Company had used the funds to pay off the loans payable. The accrued interest of \$260 was paid in cash.

15. COMMITMENTS

The Company signed a lease for premises located in Burnaby, British Columbia. The lease is for a four-year term which commenced on June 1, 2013 with a renewal option for an additional four-year term. The remaining commitment for rent and operating costs over the initial term is \$476,691; the Company has paid a security deposit of \$7,612 will be applied against the final month's rent.

16. GOVERNMENT ASSISTANCE

The Company has received assistance or signed Contribution Agreements under a number of government programs including the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP) and Agriculture Adaption Council's Canadian Agricultural Adaption Program (CAAP). The government grant receivables balance as at September 30, 2013 and June 30, 2013 are mentioned in Note 6.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

16. GOVERNMENT ASSISTANCE (continued)

Details of each of these programs are as follows:

- The Company has a Contribution Agreement with NRC-IRAP to support the Company's research and development program for \$40,750 with an expiry date as amended to April 30, 2014. For the three months ended September 30, 2013, the Company submitted no claims and a balance of \$15,000 remains under the Agreement and the Company anticipates that it will claim this amount.
- The Company has signed an Agreement with CAAP for growing trials with a maximum contribution of \$23,344 and an expiry date of October 31, 2013. No claims have been submitted under this agreement for the three months ended September 30, 2013.

17. SEGMENTED INFORMATION

The Company operates in one operating segment which encompasses research and development to identify and characterize the active ingredients in its products, and corporate activities to support research and development. Distribution of operating results in the Company's main areas of focus are as follows:

September 30, 2013	Research & Development	Corporate	Total
Total assets	351,771	135,153	486,924
Property and equipment	322,978	116,855	439,833
Revenues	-	27	27
Net loss	(153,739)	(136,433)	(290,172)
Property and equipment additions	-	2,747	2,747
Depreciation	24,875	8,167	33,042
Interest expense	-	2,206	2,206
Accretion expense	-	51	51

September 30, 2012	Plant & Operations	Research & Development	Corporate	Total
Total assets	270,655	133,709	226,403	630,767
Property and equipment	270,655	122,982	29,075	422,711
Revenues	-	-	619	619
Net loss	(344,195)	(85,261)	(98,379)	(527,835)
Property and equipment additions	12,115	16,406	-	28,521
Depreciation	144,196	9,306	5,964	159,467
Interest expense	-	-	2,507	2,507
Accretion expense	2,249	-	-	2,249

All of the Company's property and equipment is located in Canada.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the Three Months Ended September 30, 2013
(Expressed in Canadian Dollars)

18. CAPITAL MANAGEMENT

The Company manages its capital structure in order to ensure sufficient resources are available to meet operational requirements. The Company manages the components of shareholders' equity and its liabilities including shareholder loans and its bank line of credit as capital, and makes adjustments to these components in response to the Company's business objectives and the economic climate. To maintain or adjust its capital structure, the Company may attempt to issue new common shares from treasury, issue debt instruments or borrow money.

The Company expects its current capital resources, together with the proceeds from planned additional equity fundraising, will be sufficient to carry out its operations through its next operating period.

The Company does not anticipate the payment of dividends in the foreseeable future.

19. SUBSEQUENT EVENTS

- a) On October 23, 2013, the Company completed a non-brokered private placement of 42,000 units ("Units") at \$10.00 per Unit for gross proceeds of \$420,000. Each Unit consists of one common share and one warrant exercisable at \$12.00 per share expiring in five years.
- b) On October 31, 2013, the Company converted a Term Loan of \$81,231 (see Note 10) into 812 units consisting of 8,123 common shares and 8,123 warrants exercisable at \$12.00 per share expiring in five years.



TERRABIOGEN TECHNOLOGIES INC.

MANAGEMENT DISCUSSION & ANALYSIS

For the three months ended September 30, 2013

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2013**

Background

This discussion and analysis of financial position and results of operations is prepared as at November 26, 2013. The Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited interim consolidated financial statements of TerraBioGen Technologies Inc. (the "Company") as at and for the three months ended September 30, 2013 and related notes thereof which have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"). Except as otherwise disclosed, all dollar figures included therein and the following MD&A are quoted in Canadian dollars. Additional information relevant to the Company's activities can be found on SEDAR at www.sedar.com or the Company's website at www.terrabiogen.com.

Description of the Business

TerraBioGen Technologies Inc. was incorporated in British Columbia, Canada, on August 17, 1993; on January 21, 2011, the Company changed its name from International Bio Recovery Corp. The Company's common shares were traded on the TSX Venture Exchange until June 11, 2012 when they were delisted at the Company's request.

The Company has developed technologies which produce innovative, high value, environmentally progressive agricultural bioproducts that improve crop yields and suppress crop disease. TerraBioGen has a facility in Burnaby, near Vancouver, British Columbia where laboratory research and development and, plant growth room and greenhouse trials are conducted. In addition, the facility houses a laboratory pilot line for production process development to provide product for crop research and market development.

The Company is committed to research and development to continue to improve the effectiveness of its technologies, the quality of its products, and the creation of new product lines. Through collaborations with some of the leading agricultural institutes in North America and funding from the Canadian government's National Research Program, TerraBioGen is gaining an understanding of the active ingredients in its products that are responsible for the improved crop yields and suppression of disease. Further, the Company is taking steps to secure intellectual property rights to these active ingredients and fully commercialize their potential.

Forward Looking Statements

Certain information included in this discussion may constitute forward-looking statements. Forward-looking statements are based on current expectations and entail various risks and uncertainties. These risks and uncertainties could cause or contribute to actual results that are materially different than those expressed or implied. The Company disclaims any obligation or intention to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2013**

Overall Performance

The Company is a development company with minimal revenues to date from its activities.

The following selected financial information is derived from the unaudited consolidated interim financial statements of the Company. The financial statements have been prepared in accordance with IFRS.

Quarterly Financial Results

	2014	2013				2012		
	July-Sept/13	Apr-Jun/13	Jan-Mar/13	Oct-Dec/12	July-Sept/12	Apr-Jun/12	Jan-Mar/12	Oct-Dec/11
	<u>Q1 2014</u>	<u>Q4 2013</u>	<u>Q3 2013</u>	<u>Q2 2013</u>	<u>Q1 2013</u>	<u>Q4 2012</u>	<u>Q3 2012</u>	<u>Q2 2012</u>
Other income	\$ 257	\$ 230	\$ 104	\$ 3,614	\$ 1,849	\$ 10,250	\$ 1,052	\$ 700
Expenses	290,429	404,092	365,330	559,534	528,454	822,085	508,901	572,925
Gain on settlement of liabilities	-	-	-	-	-	-	-	15,762
Loss on change in decommissioning prov.	-	-	-	(44,017)	-	-	-	-
Gain on sale of assets	-	42,423	12,372	-	-	-	-	-
Net Income (Loss)	(290,172)	(362,333)	(351,960)	(598,707)	(527,835)	(811,835)	(507,849)	(556,463)
Net Income (Loss) per share	\$ (0.19)	\$ (0.24)	\$ (0.25)	\$ (0.44)	\$ (0.38)	\$ (0.70)	\$ (0.47)	\$ (0.51)
	<u>Sept. 30/13</u>	<u>June 30/13</u>	<u>Mar. 31/13</u>	<u>Dec. 31/12</u>	<u>Sept. 30/12</u>	<u>June 30/12</u>	<u>Mar. 31/12</u>	<u>Dec. 31/11</u>
Total assets	486,924	634,266	458,914	595,280	630,767	1,247,203	605,428	563,240
Long term liabilities	5,867	5,816	-	-	81,231	81,231	82,695	86,862

Comparison of the three months ended Sept. 30, 2013 to the three months ended Sept. 30, 2012

The comparative numbers are impacted by the closure of plant operations in the second quarter of 2012, resulting in no costs for plant in the current fiscal year. During the three months ended September 30, 2012, the Company was running its pilot production line.

During the three months ended September 30, 2013, the Company recorded other income of \$257 compared to other income of \$619 in the year earlier. Total expenses during the current quarter were \$290,429 compared to \$528,454 in the same period last year, a decrease of \$238,025. Administration costs increased by \$35,740, research & development costs increased by \$52,909, plant and operations costs decreased from \$197,750 to \$Nil, and depreciation costs decreased by \$126,425 from the previous quarter.

The administration cost increase of \$35,740 resulted from increases of \$29,707 in wages and consultants due to the addition of a business development person and the transfer of a plant individual, and increases of \$9,478 associated with the move to a new locations, and rent of \$6,834 (25% of rental and utilities costs are being allocated to administration whereas in previous periods, they were fully charged to plant and operations)

The research and development cost increase of \$52,909 resulted from rental costs of \$22,536 (75% of rental and utilities costs are being allocated to research and development), and an increase of \$28,661 in contractor and growing trials due to a more extensive growing trial program. No government assistance claims were made in the three months to September 30, 2013 compared to \$5,577 in the prior year.

Depreciation costs were significantly lower as the plant, including dismantling costs, and the attached office building were fully depreciated by June 30, 2013.

The net loss for the current three month period was \$290,172 or \$0.19 per share compared to a net loss of \$527,835 or \$0.38 per share in the previous year.

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2013**

Financial Condition

At September 30, 2013, the Company had total liabilities of \$437,577, a decrease of \$77,170 from June 30, 2013 primarily due to a reduction in accounts payable and accrued expenses. The Company had a working capital deficiency of \$420,725 compared to a deficiency of \$367,937 at June 30, 2013.

The Company had a term loan of \$81,231 which expired on October 31, 2013 and the lender has agreed to convert the loan in 8,123 shares and 8,123 warrants exercisable at \$12.00 per share until October 30, 2018.

The Company is dependent on cash from new financing activities in order to meet its obligations. Until the Company generates significant sales, it will be relying on new financing or license sales and any difficulty in raising new funds from these activities will have a significant impact on the Company's ability to operate. The Company anticipates that it will be able to raise new financing to cover its operating needs.

Share Capital

On June 10, 2012, the Company consolidated its shares on a 100:1 basis. As at September 30, 2013, the Company had 1,553,388 common shares outstanding; there were 289,249 share purchase warrants outstanding, exercisable at prices ranging from \$12.00 to \$15.00 and with expiry dates from December 10, 2013 to September 5, 2018. There were also 61,500 stock options outstanding, exercisable at prices ranging from \$10.00 to \$75.00 and with expiry dates ranging from March 3, 2014 to October 3, 2016.

In the year ended June 30, 2013, the Company closed private placements totalling 131,000 units at \$10.00 per unit for proceeds of \$1,310,000; each unit consisted of one common share and one warrant exercisable at \$12.00 for a period of 5 years. In September 2013, the Company closed a private placement by issuing 43,000 units for total proceeds of \$430,000. Each unit consists of one common share and one warrant exercisable at \$12.00 until September 5, 2018. In October 2013, the Company completed another private placement of 42,000 units for gross proceeds of \$420,000. Each unit consists of one common share and one warrant exercisable at \$12.00 until October 24, 2018.

Business Development

Over the past three years, the Company's primary focus has been conducting intensive research to identify and characterize the active ingredients under development. The research and development department has added additional staff and contract work and collaboration is being undertaken with several leading Canadian and US universities as well as private companies. The Company has undertaken an extensive growing trial program for 2013 in order to assess the efficacy of product formulations and delivery methods that will provide benefits to the grower and substantive return to the Company.

During the last nine months to mid-June, 2013, the Company dismantled the outdated plant at its North Vancouver facility. In June, the Company moved into new premises located in Burnaby, British Columbia. The lease is for a four year term commencing with a renewal option for an additional four year term. The remaining commitment for rent and operating costs over the initial term is \$476,691; the Company has paid a security deposit of \$7,612 and this will be applied against the final month's rent. This facility is being used both for research and development, and business development and administrative activities. TerraBioGen is actively working on the further development, formulation and patenting of additional agriculturally bioactive compounds. The Company's growing trials over the next 18 months will focus on the formulation and delivery of these materials to a wide range of horticultural and agricultural applications.

Patents

In December 2012, the Company filed provisional patents on two of its bioactive materials and is conducting further growing trials during 2013 to gather supplemental data for final patent submissions. In September 2013, the Company filed a provisional patent on a third class of bioactive materials.

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2013**

Transactions with Related Parties

During the three months ended September 30, 2013, the Company paid fees of \$15,000 for accounting and financial services to a company controlled by an officer, and consulting fees of \$3,900 to a director. In addition, directors receive a fee of \$200 for each meeting or committee meeting attended; directors' fees of \$2,200 were expensed during the three months ended September 30, 2013, \$Nil was paid to directors, and \$3,800 is owed to directors and is included in accounts payable and accrued liabilities at September 30, 2013.

Additional Information

Additional information about TerraBioGen Technologies Inc. can be found on SEDAR at www.sedar.com or on the Company's website at www.TerraBioGen.com.